Toshio Miyata, MD, PhD

Toshio Miyata

Professor, Center for Translational and Advanced Research, Tohoku University Graduate School of Medicine

Education and Career

  • Nagoya University School of Medicine, Nagoya, Japan, 1981-1986
  • Nagoya University Graduate School, Department of Internal Medicine, Nagoya, Japan, 1987-1991
  • Associate Professor, Department of Internal medicine, The Branch Hospital, Nagoya University School of Medicine, Nagoya, Japan, Assistant Professor, Department of Immunoregulation, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan, 1994-1997
  • Department of Nephrology, Hypertension and Metabolism, Tokai University School of Medicine, 1998-2007 (2004-, Professor)
  • The Institute of Medical Sciences, Tokai University (Director), 2006-

Concurrent post

  • Member of Royal Academy of Medicine in Belgium, Permanent (2004∼)
  • Member of Council, The International Society of Nephrology (∼2013)
  • Chair, Committee of the Strengthening the Partnership between JSN and ISN,
    The Japanese Society of Nephrology (2008∼)

Research Project

  • Our lab develops a new research area that combines medical science (biology), pharmacology, chemistry, and computer engineering to provide translational research. Our research is directed first toward drug discovery (development of therapeutic agents) and second to their experimental and clinical evaluation with the eventual intent to apply rapidly research results to clinical practice. The priority of our laboratory is the “acquisition of useful new molecular entities.” Indeed, we believe that it is important not only to advocate treatment concepts predicted from gene and protein data, but also to acquire tools (new molecular entities, etc) to evaluate and confirm our concepts in animal models. Specifically, our target molecules include megsin (renal disease), plasminogen activator inhibitor-1 (thrombosis, metabolism, fibrosis), prolylhydroxylase (hypoxia), glyoxalase 1 (schizophrenia), Keap1 (oxidative stress), etc. We design drug discovery strategies/construction of networks among researchers.


  1. Izuhara Y, Sada T, Yanagisawa H, Koike H, Ohtomo S, Dan T, Ito S, Nangaku M, van Ypersele de Strihou C, Miyata T. A Novel Sartan Derivative With Very Low Angiotensin II Type 1 Receptor Affinity Protects the Kidney in Type 2 Diabetic Rats. Arterioscler Thromb Vasc Biol. 2008 Jul 24.
  2. Izuhara Y, Takahashi S, Nangaku M, Takizawa S, Ishida H, Kurokawa K, van Ypersele de Strihou C, Hirayama N, Miyata T. Inhibition of plasminogen activator inhibitor-1: its mechanism and effectiveness on coagulation and fibrosis. Arterioscler Thromb Vasc Biol. 28, 672-7 (2008).
  3. Izuhara Y, Nangaku M, Takizawa S, Takahashi S, Shao J, Oishi H, Kobayashi H, van Ypersele de Strihou C, Miyata T. A novel class of advanced glycation inhibitors ameliorates renal and cardiovascular damage in experimental rat models. Nephrol Dial Transplant. 23, 497-509 (2008)
  4. Ohtomo S, Nangaku M, Izuhara Y, Yamada N, Dan T, Mori T, Ito S, van Ypersele de Strihou C, Miyata T. The role of megsin, a serine protease inhibitor, in diabetic mesangial matrix accumulation. Kidney Int. 74, 768-74 (2008).
  5. Nangaku M, Izuhara Y, Takizawa S, Yamashita T, Fujii-Kuriyama Y, Ohneda O, Yamamoto M, van Ypersele de Strihou C, Hirayama N, Miyata T. A novel class of prolyl hydroxylase inhibitors induces angiogenesis and exerts organ protection against ischemia. Arterioscler Thromb Vasc Biol. 27, 548-54 (2007).


  • t-miyata[atmark]


Page Top

Site Navigation


  • HOME
  • Contact,Access
  • Greeting
  • What is Network Medicine?
  • Mission and Design
  • Implementations
  • Investigators
  • Events
  • Fellowship Program
Tohoku University Global COE for Conquest of Signal Transduction Diseases with Network Medicine